A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis

Timeline

Start

2021-09-23

Primary completion

2022-03-25

Completion

2023-01-17

Outcome

Met primary endpoint

release “primary endpoint was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 study (clinicaltrials.gov, NCT 05003531)” innoventbio.com ↗

Drugs

Indications